This sequence change replaces valine, which is neutral and non-polar, with methionine, which is neutral and non-polar, at codon 141 of the GRIN1 protein (p.Val141Met). This variant is not present in population databases (gnomAD no frequency). This missense change has been observed in individual(s) with clinical features of GRIN1-related conditions (PMID: 35982159, 35982160, 37291213). ClinVar contains an entry for this variant (Variation ID: 860867). Invitae Evidence Modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) indicates that this missense variant is not expected to disrupt GRIN1 protein function with a negative predictive value of 95%. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance.

This variant is classified as VUS-3B. Evidence in support of pathogenic classification: Variant is present in gnomAD <0.01 (v4: 10 heterozygote(s), 0 homozygote(s)); Variant is located in the well-established functional hinge region of the N-terminal domain. Seven alternative missense changes at this residue have been functionally proven to have both loss and gain of function effects in channel activity (PMID: 23454977); Missense variant predicted to be damaging by in silico tool(s) or highly conserved with a major amino acid change; This variant has been shown to be de novo in the proband (parental status confirmed, by trio analysis). Additional information: Variant is predicted to result in a missense amino acid change from Val to Met; This variant is heterozygous; This gene is associated with both recessive and dominant disease. Missense located mostly in the N-terminal domain and NMD-predicted variants tend to be associated with autosomal recessive disease and a loss of function mechanism. Missense variants with gain of function and dominant negative consequences on protein function, usually found in the C-terminal domain, tend to be associated with dominant disease (PMID: 27164704, PMID: 29365063, OMIM); Previous evidence of pathogenicity for this variant is inconclusive. This variant has been reported once as a VUS by a clinical laboratory in ClinVar. Additionally, it was observed twice in an epilepsy cohort and once in a control cohort (PMID: 39363051); No published segregation evidence has been identified for this variant; Functional evidence for this variant is inconclusive, where assays have suggested this variant does not have a gain of function effect (personal communications); Another missense variant comparable to the one identified in this case has inconclusive previous evidence for pathogenicity. This alternative change (p.(Val141Ala)) has been reported once as a VUS by a clinical laboratory; Dominant negative, loss of function and gain of function are reported mechanisms of disease in this gene and have been associated with both autosomal dominant and recessive neurodevelopmental disorder with or without hyperkinetic movements and seizures (MIM#614254, MIM#617820).